Mega Genomics Limited logo

Mega Genomics Limited

6667.HK

HKSEHealthcareMedical - Care Facilities

Latest quote

HK$7.07

−HK$0.025 · -0.35%

Aug 24, 10:33 AM HKTData delayed

6667.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Jing Jiang
Listed since
Jun 22, 2022
Employees
206

Market position

Day range

Current HK$7.07

52-week range

Current HK$7.07

Open
HK$7.095
Previous close
HK$7.095
Volume
400
0.03× average
Average volume
13.73K
Average daily volume
Market cap
1.59B HKD
Beta
0.78
Market reference 1
50-day average
HK$7.0371
+0.47% above average
200-day average
HK$7.1258
-0.78% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
890.69M CNY
P/E (TTM)
46.62×
P/B (TTM)
1.96×
P/S (TTM)
5.5×
EV / EBITDA
17.93×
Earnings yield
2.06%
Free cash flow yield
-1.31%
Dividend yield
2.40%

Profitability & efficiency

Gross margin
47.49%
Operating margin
15.83%
Net margin
10.65%
Return on equity
4.31%
Return on assets
3.16%
Return on invested capital
5.03%

Financial health

Debt / equity
0.05×
Current ratio
3.64×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends80%47%13%-20%Gross margin, FY2020: 71.96%Gross margin, FY2021: 70.27%Gross margin, FY2022: 56.08%Gross margin, FY2023: 58.36%Gross margin, FY2025: 47.49%Operating margin, FY2020: 54.44%Operating margin, FY2021: 44.77%Operating margin, FY2022: 1.73%Operating margin, FY2023: 12.24%Operating margin, FY2025: 15.83%Net margin, FY2020: 38.92%Net margin, FY2021: 33.31%Net margin, FY2022: -12.09%Net margin, FY2023: 19.85%Net margin, FY2025: 10.65%FY2020FY2021FY2022FY2023FY2025
Gross margin FY2020 71.96%. Gross margin FY2021 70.27%. Gross margin FY2022 56.08%. Gross margin FY2023 58.36%. Gross margin FY2025 47.49%. Operating margin FY2020 54.44%. Operating margin FY2021 44.77%. Operating margin FY2022 1.73%. Operating margin FY2023 12.24%. Operating margin FY2025 15.83%. Net margin FY2020 38.92%. Net margin FY2021 33.31%. Net margin FY2022 -12.09%. Net margin FY2023 19.85%. Net margin FY2025 10.65%.

Income trends

Revenue

247.15M CNY+63.35%

Operating income

39.13M CNY+111.19%

Net income

26.32M CNY-12.37%
Income trends across reported periods273.63M CNY167.72M CNY61.81M CNY−44.09M CNYRevenue, FY2020: 203.22M CNYRevenue, FY2021: 237.19M CNYRevenue, FY2022: 145.73M CNYRevenue, FY2023: 151.3M CNYRevenue, FY2025: 247.15M CNYOperating income, FY2020: 110.63M CNYOperating income, FY2021: 106.19M CNYOperating income, FY2022: 2.53M CNYOperating income, FY2023: 18.53M CNYOperating income, FY2025: 39.13M CNYNet income, FY2020: 79.1M CNYNet income, FY2021: 79.02M CNYNet income, FY2022: −17.62M CNYNet income, FY2023: 30.04M CNYNet income, FY2025: 26.32M CNYFY2020FY2021FY2022FY2023FY2025
Revenue FY2020 203.22M CNY. Revenue FY2021 237.19M CNY. Revenue FY2022 145.73M CNY. Revenue FY2023 151.3M CNY. Revenue FY2025 247.15M CNY. Operating income FY2020 110.63M CNY. Operating income FY2021 106.19M CNY. Operating income FY2022 2.53M CNY. Operating income FY2023 18.53M CNY. Operating income FY2025 39.13M CNY. Net income FY2020 79.1M CNY. Net income FY2021 79.02M CNY. Net income FY2022 −17.62M CNY. Net income FY2023 30.04M CNY. Net income FY2025 26.32M CNY.
Metric (CNY)FY2025FY2023FY2022FY2021FY2020
Revenue247.15M CNY151.3M CNY145.73M CNY237.19M CNY203.22M CNY
Cost of goods sold129.79M CNY63M CNY64M CNY70.51M CNY56.98M CNY
Gross profit117.36M CNY88.3M CNY81.72M CNY166.68M CNY146.24M CNY
Research and development17.29M CNY24.73M CNY19.44M CNY11.41M CNY4.45M CNY
Selling, general, and administrative61.65M CNY75.21M CNY77.79M CNY25.62M CNY20.58M CNY
Operating expenses78.24M CNY69.77M CNY76.92M CNY45.32M CNY36.87M CNY
Interest income6.79M CNY722K CNY1.39M CNY269K CNY344K CNY
Interest expense1.33M CNY1.12M CNY719K CNY6.91M CNY16.55M CNY
Depreciation and amortization15.49M CNY15.12M CNY15.28M CNY13.87M CNY14.04M CNY
Operating income39.13M CNY18.53M CNY2.53M CNY106.19M CNY110.63M CNY
Net income26.32M CNY30.04M CNY−17.62M CNY79.02M CNY79.1M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.19

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.310.13-0.05-0.23Q2 '21Q4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24
Q2 2021, reported Jun 30, 2021: actual 0.193, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 0.266, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 11, 2022: actual 0.104, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 31, 2022: actual -0.19, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 0.171, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Dec 31, 2023: actual -0.028, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 30, 2024: actual 0.189, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates181.21M136.33M91.45M46.57MQ2 '21Q4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24
Q2 2021, reported Jun 30, 2021: actual 116.26M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 171.84M HKD, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 11, 2022: actual 114.28M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 31, 2022: actual 54.79M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 106.93M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Dec 31, 2023: actual 58.02M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 30, 2024: actual 115.22M HKD, estimate —, surprise —, Comparison unavailable.

6667.HK peers

Continue in GoAI

Research 6667.HK

research.disclaimer